Mayne Pharma Group Ltd. · ASX:MYX
Mayne Pharma — Shareholder Meeting (June 2025)
16 slides from Mayne Pharma's shareholder meeting presentation, Jun 18, 2025
Slide 1: Chair's Address and Presentation at the Scheme Meeting
ASX Announcement CHAIR’S ADDRESS AND PRESENTATION AT THE SCHEME MEETING 18 June 2025, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) (Mayne Pharma) refers to the scheme of arrangement between Mayne Pharma and its shareholders under which Cosette Pharmaceuticals, Inc. (Cosette) (via Coset
Slide 2: ASX Announcement - About Mayne Pharma
ASX Announcement For further information contact: Dr Tom Duthy +61 402 493 727 ir@maynepharma.com About Mayne Pharma Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals to offer patients better, safe and more accessible medicines. Mayne Pha
Slide 3: Scheme Meeting - Chair's Script
Mayne Pharma Group Limited ACN 115 832 963 SCHEME MEETING – CHAIR’S SCRIPT Wednesday, 18 June 2025 at 10am (AEST) Welcome Welcome everyone. I am Frank Condella, Chair of Mayne Pharma. On behalf of the Mayne Pharma Board and the management team, I would like to welcome our shareholders, or their prox
Slide 4: Procedural matters and summary of recommendation
a summary of the key reasons for the Mayne Pharma directors’ recommendation in respect of the Scheme and the Independent Expert’s conclusion; a summary of the status of the conditions precedent to the Scheme becoming effective and the indicative timetable for the implementation of the Scheme; an
Slide 5: Voting procedures
For those participating online, voting for all resolutions is open and will remain open during the meeting. If you are eligible to vote at this meeting, you will see a vote icon displayed on your screen. Click on this icon, which will present you with voting options. To cast your vote, select one of
Slide 6: Scheme conditions and Cosette termination dispute
to enable the dispute with Cosette, which was the subject of the Supplementary Scheme Booklet and which I will discuss more, to be determined by the Court. Any variation to the Court timetable, the Second Court Date, or any other Key Dates relating to the Scheme will be notified to Shareholders via
Slide 7: Directors' recommendation and Independent Expert's conclusion
Shareholders should have regard to the interests of Mayne Pharma directors when considering the directors’ recommendation. These details are disclosed in Sections 11.1 and 11.2 of the Scheme Booklet. Prior to today’s meeting, Mayne Pharma directors who hold or control Mayne Pharma shares have instru
Slide 8: Voting thresholds and Q&A
• At least 75% of the total number of votes cast on the Scheme Resolution by eligible Mayne Pharma Shareholders present and voting at the Scheme Meeting; and • A majority in number (that is, more than 50%) of eligible Mayne Pharma Shareholders present and voting at the Scheme Meeting. Q&A We will no
Slide 9: Mayne Pharma Group Limited Scheme Meeting
Mayne Pharma Group Limited Scheme Meeting 10.00am (Melbourne Time) 18 June 2025
Slide 10: Introduction – Directors
Introduction – Directors Frank Condella David Petrie Prof Bruce Robinson Anne Lockwood Chair Non-Executive Director Non-Executive Director Non-Executive Director Shawn Patrick O’Brien Dr Katie Macfarlane Ann Custin Patrick Blake CEO & Managing Director Non-Executive Director Non-Executive Director N
Slide 11: How to ask a question
How to ask a question ● To ask a written question select the Q & A icon ● Select the topic your question relates to from the drop-down list ● Type your question in the text box and press the send button ● To ask a verbal question follow the instructions below the broadcast window 3
Slide 12: How to vote
How to vote ● When the poll is open, select the vote icon at the top of the screen ● To vote, select either For, Against or Abstain ● You will see a vote confirmation ● To change or cancel your vote “click here to change your vote” at any time until the poll is closed 4
Slide 13: The Scheme Resolution
The Scheme Resolution To consider and, if thought fit, to pass the following resolution in accordance with section 411(4)(a)(ii) of the Corporations Act: “That pursuant to, and in accordance with, section 411 of the Corporations Act 2001 (Cth), the scheme of arrangement proposed between Mayne Pharma
Slide 14: The Scheme Resolution – Proxy Results
The Scheme Resolution – Proxy Results Proxy results – Shares For Against Abstain Open 35,225,802 339,546 154,048 172,271 (98.57%) (0.95%) (0.48%) Proxy results - Holders For Against Abstain Open 699 94 9 60 6
Slide 15: Poll
Poll
Slide 16: Contacts
Contacts For further information contact: Dr Tom Duthy Investor Relations +61 402 493 727 ir@maynepharma.com You deserve tomorrow. 8